Page last updated: 2024-10-22

ambroxol and Glycogen Storage Disease Type II

ambroxol has been researched along with Glycogen Storage Disease Type II in 1 studies

Ambroxol: A metabolite of BROMHEXINE that stimulates mucociliary action and clears the air passages in the respiratory tract. It is usually administered as the hydrochloride.

Glycogen Storage Disease Type II: An autosomal recessively inherited glycogen storage disease caused by GLUCAN 1,4-ALPHA-GLUCOSIDASE deficiency. Large amounts of GLYCOGEN accumulate in the LYSOSOMES of skeletal muscle (MUSCLE, SKELETAL); HEART; LIVER; SPINAL CORD; and BRAIN. Three forms have been described: infantile, childhood, and adult. The infantile form is fatal in infancy and presents with hypotonia and a hypertrophic cardiomyopathy (CARDIOMYOPATHY, HYPERTROPHIC). The childhood form usually presents in the second year of life with proximal weakness and respiratory symptoms. The adult form consists of a slowly progressive proximal myopathy. (From Muscle Nerve 1995;3:S61-9; Menkes, Textbook of Child Neurology, 5th ed, pp73-4)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lukas, J1
Pockrandt, AM1
Seemann, S1
Sharif, M1
Runge, F1
Pohlers, S1
Zheng, C1
Gläser, A1
Beller, M1
Rolfs, A1
Giese, AK1

Other Studies

1 other study available for ambroxol and Glycogen Storage Disease Type II

ArticleYear
Enzyme enhancers for the treatment of Fabry and Pompe disease.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2015, Volume: 23, Issue:3

    Topics: 1-Deoxynojirimycin; Acetylcysteine; alpha-Galactosidase; alpha-Glucosidases; Ambroxol; Bezafibrate;

2015